Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1989-05-18
1992-10-06
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 851, 424 858, 424 8591, 424 88, 424 92, 424 89, 424 90, 424 91, 514885, 514 2, 530351, 53038822, 53038875, A61K 3900, A61K 3702
Patent
active
051529807
ABSTRACT:
A method of inducing tolerance to a foreign antigen in a mammal, by administering an IL-2-receptor-positive-cell-destroying amount of a substance capable of destroying IL-2-receptor-positive cells which are newly activated in response to the antigen, to a degree which supresses the mammal's humoral immune response to a subsequent challenge with the antigen.
REFERENCES:
patent: 4545985 (1985-10-01), Pastan et al.
patent: 4675382 (1987-06-01), Murphy
patent: 4681760 (1987-07-01), Fathman
patent: 4695459 (1987-09-01), Steinman et al.
patent: 4738927 (1988-04-01), Taniguchi et al.
patent: 4904481 (1990-02-01), Fathman
Fahey et al., Annal. of Internal Med, 106, 1987, pp. 257-274.
Hwang et al. (1987) Cell 48:129.
Bishai et al. (1987) J. Bact. 169:1554.
Uchiyama et al. (1981) J. Immunol. 126:1393.
Lorberboum-Galski et al., Proc. Natl. Acad. Sci., USA, vol. 85, Mar. 1988, pp. 1922-1926.
Fidler, J. M. et al., Chemical Abstracts, vol. 78, No. 13, Apr. 2, 1973, pp. 315-316.
Leonard et al. (1983) P.N.A.S. U.S.A. 80:6957.
Gaulton et al. (1985) Clin. Immunl. and Immunopath. 36:18.
Kelley et al., "Anti-Interleukin 2 Receptor Antibody Suppresses Delayed-Type Hypersensitivity to Foreign and Syngeneic Antigens" (1986) Journal of Immunology, vol. 137, 2122-2124.
Kelley et al., "Anti-Interleukin 2 Receptor Antibody Suppresses Murine Diabetic Insulitis and Lupus Nephritis" (1988) Journal of Immunology, vol. 140, 001-003.
Kirkman et al., "The Effect of Anti-Interleukin-2 Receptor Monoclonal Antibody on Allograft Rejection", (1985) Transplantation, vol. 40, No. 6, pp. 719-722.
Gaulton et al., "Characterization of a Monoclonal Rat Anti-mouse Interleukin 2 (IL-2) Receptor Antibody and Its Use in the Biochemical Characterization of the Murine IL-2 Receptor", (1985), vol. 40, pp. 18-29.
Schneider et al., "Development of Suppressor Lymphocytes During Acute Rejection of Rat Cardiac Allografts and Preservation of Suppression by Anti-IL-2-Receptor Monoclonal Antibody" (1986) Transplantation, vol. 42, No. 2 pp. 191-196.
Volk et al., "Suppression of the local grafts-vs.-host reaction in rats by treatment with a monoclonal antibody specific for the interleukin 2 receptor" (1986) Eur. J. Immunol. 16:1309-1312.
Kupiec-Weglinski et al., "Interleukin-2 Receptor Targeted Therapy in Organ Transplantation" American College of Surgeons 1986 Surgical Forum vol. XXXVII, pp. 374-377.
Kelley et al., "Immunosuppression by Anti-Interleukin-2 Receptor Antibody but Not Anti-L3T4 Requires Terminal Complement Components" Transplantation Proceedings, vol. XIX, No. 1, 1987 p. 617.
Kupiec-Weglinski et al., "Anti-Interleukin-2 Receptor (IL-2R) Antibody Against Rejection of Organ Grafts" Transplantation Proceedings, vol. XIX, No. 1, 1987, pp. 591-593.
Kelley et al., "Inhibitory Effects of Anti-Interleukin 2 Receptor and Anti-L3T4 Antibodies on Delayed Type Hypersensitivity: The Role of Complement and Epitope", The Journal of Immunology (1987) vol. 138, 2771-2775.
Strom et al., "Toward More Selective Therapies to Block Undesired Immune Responses", Kidney International, vol. 35 (1989), pp. 1026-1033.
Hahn et al., "Curing BB rats of freshly manifested diabetes by short-term Treatment with a combination of a monoclonal anti-interleukin 2 receptor antibody and a subtherapeutic dose of cyclosporin A", Eur. J. Immunol. 1987, 17: 1075-1078.
Hahn et al., "Prolongation of rat pancreatic islet allograft survival by treatment of recipient rats with monoclonal anti-interleukin-2 receptor antibody and cyclosporin", Diabetologia
Funding for the work described herein was provided by the federal government, which has certain rights in the invention.
Kelley Vicki E.
Strom Terry B.
Brigham and Women's Hospital
Draper Garnette D.
The Beth Israel Hospital Association
LandOfFree
Induction of tolerance to a foreign antigen IL-2 receptor-bindin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Induction of tolerance to a foreign antigen IL-2 receptor-bindin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Induction of tolerance to a foreign antigen IL-2 receptor-bindin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1187703